Ryan Donnelly, Alessandro N Franciosi, Sarah H Forde, Michael McDermott, Michael P Keane, David J Murphy, Emmet E McGrath, Cormac McCarthy
{"title":"Deciphering the Role of Fluorodeoxyglucose-Positron Emission Tomography/CT Imaging in the Management of Sarcoidosis.","authors":"Ryan Donnelly, Alessandro N Franciosi, Sarah H Forde, Michael McDermott, Michael P Keane, David J Murphy, Emmet E McGrath, Cormac McCarthy","doi":"10.1016/j.chest.2025.02.017","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>2-Deoxy-2-[<sup>18</sup>F]fluoro-d-glucose (FDG)-PET/CT imaging has utility in identifying sites of active sarcoidosis. However, the role of FDG-PET/CT imaging in predicting treatment response and guiding therapy outside of cardiac disease is yet to be completely understood.</p><p><strong>Research question: </strong>Do physicians agree on the utility of FDG-PET/CT imaging in sarcoid cases, and do they agree on the appropriate treatment response, based on the associated reports?</p><p><strong>Study design and methods: </strong>Physician respondents were presented with a series of anonymized sarcoidosis case vignettes. The perceived utility of FDG-PET/CT imaging in each case, as well as the ultimate treatment decision following provision of FDG-PET/CT results, was assessed. Interrater agreement was assessed overall and per-case vignette specialty, using the Gwet agreement coefficient (AC1).</p><p><strong>Results: </strong>Respondents (n = 215) were predominantly respiratory physicians (86.78%) experienced in sarcoidosis management (94.39%), and one-third of whom had > 20 years of experience (32.66%). Pulmonary sarcoidosis case vignettes had the lowest rates of FDG-PET/CT endorsement among surveyed subspecialties (38%-64%). Overall interrater agreement was assessed among physicians who positively endorsed FDG-PET/CT imaging. Treatment rationalization based on FDG-PET/CT report approached near-chance agreement for pulmonary cases (AC1 = 0.178) (n = 217; 95% CI, 0.125-0.234; P = .07) and multisystem cases (AC1 = 0.296) (n = 168; 95% CI, 0.066-0.477; P = .41), whereas agreement was highest for cases of cardiac sarcoidosis (AC1 = 0.797) (n = 374; 95% CI, 0.759-0.838; P < .05).</p><p><strong>Interpretation: </strong>Our results indicate low agreement between physicians regarding their management of pulmonary sarcoidosis following FDG-PET/CT imaging. This highlights a need for further research and clarity concerning the role of FDG-PET/CT imaging in the therapeutic management of pulmonary sarcoidosis.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"146-155"},"PeriodicalIF":8.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2025.02.017","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: 2-Deoxy-2-[18F]fluoro-d-glucose (FDG)-PET/CT imaging has utility in identifying sites of active sarcoidosis. However, the role of FDG-PET/CT imaging in predicting treatment response and guiding therapy outside of cardiac disease is yet to be completely understood.
Research question: Do physicians agree on the utility of FDG-PET/CT imaging in sarcoid cases, and do they agree on the appropriate treatment response, based on the associated reports?
Study design and methods: Physician respondents were presented with a series of anonymized sarcoidosis case vignettes. The perceived utility of FDG-PET/CT imaging in each case, as well as the ultimate treatment decision following provision of FDG-PET/CT results, was assessed. Interrater agreement was assessed overall and per-case vignette specialty, using the Gwet agreement coefficient (AC1).
Results: Respondents (n = 215) were predominantly respiratory physicians (86.78%) experienced in sarcoidosis management (94.39%), and one-third of whom had > 20 years of experience (32.66%). Pulmonary sarcoidosis case vignettes had the lowest rates of FDG-PET/CT endorsement among surveyed subspecialties (38%-64%). Overall interrater agreement was assessed among physicians who positively endorsed FDG-PET/CT imaging. Treatment rationalization based on FDG-PET/CT report approached near-chance agreement for pulmonary cases (AC1 = 0.178) (n = 217; 95% CI, 0.125-0.234; P = .07) and multisystem cases (AC1 = 0.296) (n = 168; 95% CI, 0.066-0.477; P = .41), whereas agreement was highest for cases of cardiac sarcoidosis (AC1 = 0.797) (n = 374; 95% CI, 0.759-0.838; P < .05).
Interpretation: Our results indicate low agreement between physicians regarding their management of pulmonary sarcoidosis following FDG-PET/CT imaging. This highlights a need for further research and clarity concerning the role of FDG-PET/CT imaging in the therapeutic management of pulmonary sarcoidosis.
期刊介绍：
At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
